-- Dr. Mariana
Castells, M.D., Ph.D., a renowned researcher and clinical
expert in mast cell diseases, will join members of Blueprint
Medicines' management team to provide a perspective on the mast
cell as a promising target for treating allergic and inflammatory
disease on April 25, 2024, at
10:00 a.m. ET --
-- First in a series of planned webcasts
hosted by Blueprint to highlight evolving science around R&D
and pipeline strategy --
CAMBRIDGE, Mass., April 11,
2024 /PRNewswire/ -- Blueprint Medicines Corporation
(NASDAQ: BPMC) today announced it will launch a webcast series to
provide scientific perspectives and showcase the company's research
and development strategy. The first event in this series will
feature Dr. Mariana Castells, a
renowned leader in mast cell research and clinical expert in
allergic/inflammatory diseases, as a guest speaker.
Mast cells are increasingly implicated in the pathogenesis of a
wide range of allergic and inflammatory conditions, leading to an
acceleration in research into mast cell biology. This webcast will
focus on the biology of mast cells, including their essential role
as drivers of and contributors to inflammatory responses, their
core involvement in biological pathways relevant to an array of
allergic and inflammatory diseases, and Blueprint's approach to
modulating mast cells and building a pipeline in allergic and
inflammatory disease. The webcast will include a presentation and
live Q&A.
Title: The powerful mast cell: a promising target
for treating allergic and inflammatory diseases
Date: Thursday, April 25, 2024
Time: 10:00 a.m. ET
Presenters:
Guest speaker
- Mariana Castells, M.D., Ph.D.,
Director, Mastocytosis Center at Brigham and Women's Hospital
Blueprint Medicines speakers
- Fouad Namouni, M.D., President, Research & Development
- Becker Hewes, M.D., Chief Medical Officer
- Percy H. Carter, Ph.D., MBA,
Chief Scientific Officer
To access the live webcast, please dial 833-470-1428 (domestic)
or 404-975-4839 (international) and refer to conference ID 814168.
A live webcast of the event will be available under "Events and
Presentations" in the Investors & Media section of the
Blueprint Medicines website at http://ir.blueprintmedicines.com/.
The archived webcast will be available on Blueprint Medicines'
website approximately two hours after each event and will be
available thereafter.
Blueprint plans to host the next webcast in the series in the
second half of 2024.
About Blueprint Medicines
Blueprint Medicines is a fully integrated, commercial-stage,
global biopharmaceutical company that invents life-changing
medicines in two core, strategic areas of allergy/inflammation and
oncology/hematology. We pursue discovery, development, and
commercialization of therapies that potently and selectively target
known drivers of disease, with focused investment in therapeutic
areas where we can leverage our core expertise and business
infrastructure to bring scale to our science. We are bringing
AYVAKIT®/AYVAKYT® (avapritinib) to people living with systemic
mastocytosis (SM) in the U.S. and Europe. Additionally, we have a pipeline of
research and development programs that range from early science to
advanced clinical trials in mast cell-mediated diseases, including
SM and chronic urticaria, and oncology including breast cancer, and
other solid tumors vulnerable to CDK2 inhibition. For more
information, visit www.BlueprintMedicines.com and follow
us on X (formerly Twitter; @BlueprintMeds)
and LinkedIn.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-to-host-webcast-and-conference-call-highlighting-emerging-opportunities-for-mast-cell-targeted-therapeutics-302113503.html
SOURCE Blueprint Medicines Corporation